Dicerna doses first patient in trial of RNA inhibitor for chronic HBV

Dicerna dosed the first patient in a phase 1 clinical trial for DCR-HBVS, an investigational GalXCTM-based therapy for the treatment of chronic hepatitis B, according to a press release.
“Dosing of the first patient in the DCR-HBVS-101 trial signals a major step toward our ultimate goal of developing a viable therapeutic option for patients with chronic hepatitis B virus, a serious liver infection that can result in advanced liver disease or liver cancer if not treated effectively,” Ralf Rosskamp, MD, chief medical officer of Dicerna, said in the release. “Based upon our

Source link

Related posts

Collagen Signature Helps Predict Lymph Node Status in Early Gastric Ca


Recent Decline in Hepatocellular Carcinoma Rates in the United States


Discontinuing popular over-the-counter vitamin can lead of reversal of retinal swelling


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy